Dr. Fleming is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3000 Coliseum Dr
Suite 104
Hampton, VA 23666Phone+1 757-827-9400Fax+1 757-827-9320
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2003 - 2006
Temple University HospitalResidency, Internal Medicine, 1999 - 2002
The University of Toledo College of MedicineClass of 1999
Certifications & Licensure
VA State Medical License 2006 - 2026
NY State Medical License 2003 - 2007
NJ State Medical License 2002 - 2003
PA State Medical License 2000 - 2002
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Mitoxantrone ± Cetuximab 2nd Line Androgen Independent Prostate Cancer (AIPC) Start of enrollment: 2008 May 01
- First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma Start of enrollment: 2010 Dec 01
- First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma Start of enrollment: 2012 Jan 01
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsTrue-PositiveF-Flotufolastat Lesions in Patients with Prostate Cancer Recurrence with Baseline-Negative Conventional Imaging: Results from the Prospective, Phase 3, Mu...Mark T Fleming, Rick Hermsen, Andrei S Purysko, Albert Chau, Phillip Davis
Journal of Nuclear Medicine. 2024-07-01 - 2 citationsProstate Cancer Foundation Screening Guidelines for Black Men in the United States.Isla P Garraway, Sigrid V Carlsson, Yaw A Nyame, Jason L Vassy, Marina Chilov
NEJM Evidence. 2024-05-01 - Infigratinib Versus Placebo for Patients with High-risk Resected Urothelial Cancer Bearing an FGFR3 Genomic Alteration: Results from the PROOF302 Phase 3 Trial.Sumanta K Pal, Petros Grivas, Shilpa Gupta, Nazli Dizman, Zeynep Zengin
European Urology. 2024-04-04
Journal Articles
- Phase 1 Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate CancerMark T Fleming, Luke T Nordquist, William R Berry, Clinical Cancer Research
Press Mentions
AUA 2022: Late-Breaking Plenary HighlightsJuly 27th, 2022- Creating an Inclusive Environment in Your Oncology Practice with Mark Fleming, MDJuly 11th, 2022
- Oncologists “In a Quandary” over Lack of Second-Line Guidance in Bladder CancerFebruary 21st, 2024
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
